These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3890700)

  • 41. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

  • 42. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
    Biesemeyer H; Ludin HP; Ringwald E
    J Neurol; 1983; 230(1):19-23. PubMed ID: 6194269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lergotrile in Parkinson's disease.
    Lieberman AN; Kupersmith M; Estey E; Goldstein M
    Lancet; 1976 Sep; 1(7984):515-6. PubMed ID: 74475
    [No Abstract]   [Full Text] [Related]  

  • 44. The pharmacology of mesulergine.
    Pfeiffer RF
    Clin Neuropharmacol; 1985; 8(1):64-72. PubMed ID: 3884151
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG; Wilcox PG; Churg A; Fleetham JA
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
    Baas H; Schneider E; Fischer PA; Japp G
    J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
    J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
    [No Abstract]   [Full Text] [Related]  

  • 49. Original research: The perioperative experience of patients with Parkinson's disease: a qualitative study.
    Anderson LC; Fagerlund K
    Am J Nurs; 2013 Feb; 113(2):26-32; quiz 33. PubMed ID: 23334560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of lergotrile on schizophrenia & drug induced parkinsonism.
    Small JG; Kellams JJ; Milstein V; Klapper M; Lemberger L
    Commun Psychopharmacol; 1977; 1(5):461-7. PubMed ID: 23919
    [No Abstract]   [Full Text] [Related]  

  • 52. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M; MacIver DH
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
    Hutton JT; Morris JL; Brewer MA
    Neurology; 1993 Mar; 43(3 Pt 1):613-6. PubMed ID: 8451010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial treatment of parkinsonism with 8-alpha-amino-ergoline.
    Teräväinen H; Huttunen J; Hietanen M
    Neurology; 1985 Jan; 35(1):83-7. PubMed ID: 3966006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parkinson's disease: new drugs help but no cure on the horizon.
    González ER
    JAMA; 1981 Jul; 246(1):11-2. PubMed ID: 7241717
    [No Abstract]   [Full Text] [Related]  

  • 56. [Experience with amysil treatment of patients with vascular parkinsonism].
    Kamenetskiĭ VK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(9):56-9. PubMed ID: 2692361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CQA 206-291 in Parkinson's disease.
    Pfeiffer RF; Hofman R
    Clin Neuropharmacol; 1991 Apr; 14(2):170-8. PubMed ID: 1673089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose CU 32-085 (mesulergine) in previously untreated Parkinson's disease.
    Bonnet AM; Esteguy M; Guimaraes J; Lhermitte F; Agid Y
    Neurology; 1984 Aug; 34(8):1127-8. PubMed ID: 6540396
    [No Abstract]   [Full Text] [Related]  

  • 59. Double-blind assessment of potential pergolide-induced cardiotoxicity.
    Kurlan R; Miller C; Knapp R; Murphy G; Shoulson I
    Neurology; 1986 Jul; 36(7):993-5. PubMed ID: 3520383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [P4, a new substance for the treatment of Parkinson syndrome. Initial results of a clinical trial].
    Herbst A
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():77-82. PubMed ID: 829639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.